AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25585031
Drug: 2013 AHA/ACC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2013 AHA/ACC guidelines approach (maximization of statin therapy at high-intensity for patients aged ≤75 years and moderate- or high-intensity for patients >75 years)
Trial: 25585031
Drug: Previous guidelines
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous guidelines approach (achievement of LDL-C target < 1.8 mmol/l, reduction of LDL-C ≥ 50% or intensification of statin)
Trial: 25585528
Drug: Etravirine 400
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etravirine 400 mg and darunavir/ritonavir 800/100 mg once-daily regimen
Trial: 25586396
Drug: Psilocybin administered
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin administered orally in one or two supervised sessions in addition to Motivational Enhancement Therapy
Trial: 25586726
Drug: Dosing recommendations
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing recommendations for EACA based on weight: weight <25 kg, 100 mg kg(-1) loading dose and 40 mg kg(-1) h(-1) infusion; weight ≤25 kg-<50 kg, 100 mg kg(-1) loading dose and 35 mg kg(-1) h(-1) infusion; weight ≥50 kg, 100 mg kg(-1) loading dose and 30 mg kg(-1) h(-1) infusion.
Trial: 25586952
Drug: Escalating radiation
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating radiation dose with simultaneous integrated boost (SIB) to the pre-treatment 50% SUVmax area of the primary tumor, up to 70Gy
Trial: 25589626
Drug: ChiLob7/4 (agonistic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChiLob7/4 (agonistic anti-CD40 antibody) at 200 mg × 4 doses, administered by IV infusion weekly for 4 doses.
Trial: 25589626
Drug: ChiLob7/4 (agonistic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChiLob7/4 (agonistic anti-CD40 antibody) at doses above 16 mg.
Trial: 25589626
Drug: ChiLob7/4 (agonistic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChiLob7/4 (agonistic anti-CD40 antibody) at doses between 1.6 mg and 50 mg.
Trial: 25589626
Drug: ChiLob7/4 (agonistic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChiLob7/4 (agonistic anti-CD40 antibody) at doses that can be administered safely.
Trial: 25589626
Drug: ChiLob7/4 (agonistic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChiLob7/4 (agonistic anti-CD40 antibody) at doses from 50 mg upward.
Trial: 25590177
Drug: Magnetic-controlled capsule
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic-controlled capsule endoscopy (MCE)
Trial: 25590835
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day) and capecitabine (1000 mg/m2 twice daily on days 1-14)
Trial: 25591040
Drug: Trabectedin 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 0.9 mg/m2 on day 1 and gemcitabine 700 mg/m2 on days 1 + 8, every 3 weeks
Trial: 25591040
Drug: Trabectedin 0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 0.7 mg/m2 plus gemcitabine 700 mg/m2
Trial: 25592331
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV ibuprofen (800 mg) administered over 5 to 10 minutes preoperatively
Trial: 25592632
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg orally once a day in 6-week cycles (4 weeks of treatment followed by 2 weeks without treatment)
Trial: 25593079
Drug: Intrathecal injection
RxNorm normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal injection of CD133-positive enriched bone marrow progenitor cells
Trial: 25594861
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate (TU) treatment for 0.8 years (median 0.5; 1.3)
Trial: 25595221
Drug: OnabotulinumtoxinA treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA treatment, mean dose 189.8 ± 87.1U, average treatment intervals of 14.6 and 15.1 weeks.
Trial: 25596263
Drug: Vorinostat 200
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat 200 mg orally twice daily on days 1-14 and rituximab 375 mg/m² intravenously on day 1 of a 21-day cycle.
Trial: 25599347
Drug: Treatment interruptions
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment interruptions or poor medication adherence
Trial: 25603113
Drug: Oral washes
RxNorm normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral washes (OW)
Trial: 25603823
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IFNα and soluble Flt-1
Trial: 25603823
Drug: Soluble Flt-1
RxNorm normalized name: 18F-FLT
DrugBank: Alovudine F-18 (DB14930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble Flt-1 treatment on human endothelial cells
Trial: 25603822
Drug: Suboxone 2.0/0.5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suboxone 2.0/0.5-mg tablet
Trial: 25604779
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral nutritional supplements (ingestion of ⩾ 11/15 units)
Trial: 25604779
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral nutritional supplements
Trial: 25605368
Drug: Mogamulizumab (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mogamulizumab (1.0 mg/kg)
Trial: 25605368
Drug: Mogamulizumab (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mogamulizumab (0.1, 0.3, and 1.0 mg/kg)
Trial: 25605552
Drug: Once-daily trientine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily trientine (15 mg/kg)
Trial: 25605745
Drug: Romidepsin at
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin at a dose of 14 mg/m(2) on days 1, 8, and 15 of 28-day cycles
Trial: 25605745
Drug: Romidepsin treatment
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin treatment
Trial: 25609248
Drug: OPB-51602 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPB-51602 at 5 mg intermittently
Trial: 25609248
Drug: OPB-51602 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPB-51602 at 4 mg continuously
Trial: 25609248
Drug: OPB-51602 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPB-51602 at 4 mg intermittently (Cohort B)
Trial: 25609248
Drug: OPB-51602 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPB-51602 at 2 mg and 4 mg intermittently
Trial: 25609248
Drug: Continuous dosing
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous dosing of OPB-51602
Trial: 25609248
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing of OPB-51602
Trial: 25609320
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (300 mg on day 1, 600 mg on day 2, adjusted to 400-800 mg thereafter)
Trial: 25609333
Drug: C1-inhibitor (Berinert)
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-inhibitor (Berinert) as on-demand therapy
Trial: 25609333
Drug: C1-inhibitor (Berinert)
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-inhibitor (Berinert) for prophylactic administration
Trial: 25609333
Drug: C1-inhibitor (Berinert)
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-inhibitor (Berinert) in home setting
Trial: 25609333
Drug: C1-inhibitor (Berinert)
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-inhibitor (Berinert) overall safety
Trial: 25609333
Drug: C1-inhibitor (Berinert)
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-inhibitor (Berinert) thromboembolic events
Trial: 25609333
Drug: C1-inhibitor (Berinert)
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-inhibitor (Berinert) safety profile
Trial: 25612635
Drug: Oxaliplatin 60
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 60 mg/m(2)/week on days 1, 8, 22, and 29 plus S-1 80 mg/m(2)/day on days 1-5, 8-12, 22-27, and 29-33 with 50.4 Gy radiotherapy
Trial: 25613597
Drug: Less education,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less education, younger age at injury, current or past treatment of depression, bipolar disorder or schizophrenia
Trial: 25613716
Drug: dTpa booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dTpa booster dose (0.5mg or 0.3mg formulations)
Trial: 25613716
Drug: dTpa booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dTpa booster dose (0.133mg group received 0.5mg formulation)
Trial: 25613716
Drug: dTpa booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dTpa booster dose
Trial: 25614165
Drug: IW001 (col(V)
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IW001 (col(V) oral immunotherapeutic)
Trial: 25614940
Drug: new agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: new agents under investigation
Trial: 25614962
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir (DCV) 60 mg plus Sofosbuvir (SOF) 400 mg once-daily for 12 weeks
Trial: 25617154
Drug: Individualized yoga
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized yoga conducted three times weekly for three weeks.
Trial: 25617726
Drug: Lubiprostone treatment
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lubiprostone treatment for four weeks
Trial: 25617726
Drug: Lubiprostone treatment
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lubiprostone treatment
Trial: 25620457
Drug: Cortrosyn(™) stimulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortrosyn(™) stimulated aldosterone level of 5 ng/dl (0·14 nmol/l)
Trial: 25620668
Drug: Capsule colonoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule colonoscopy
Trial: 25621498
Drug: Reduced decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced decitabine dosages (0.1-0.2 mg/kg/day)
Trial: 25622640
Drug: NHS-IL2 (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NHS-IL2 (0.15 mg/kg, 0.30 mg/kg, 0.45 mg/kg) plus radiotherapy (5x 4 Gy)
Trial: 25622640
Drug: NHS-IL2 alone
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NHS-IL2 alone (5 mg/kg; days 7-9) plus fractionated radiotherapy (3.6 Gy; days 0-4) plus cisplatin (4 mg/kg; day 0)
Trial: 25622723
Drug: Immunophenotyping analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunophenotyping analysis using 12-color antibody panels.
Trial: 25622919
Drug: Edrophonium (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium (10 mg) intravenous injection
Trial: 25623151
Drug: Intranasal evaporative
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal evaporative cooling
Trial: 25624177
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy and radiation
Trial: 25624326
Drug: Depot medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot medroxyprogesterone acetate (DMPA) with twice-daily lopinavir (LPV) plus low-dose ritonavir (RTV)
Trial: 25624327
Drug: Low-dose isavuconazole
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose isavuconazole (400/200/200 mg loading doses on day 1 and 200/200 mg on day 2, followed by 200 mg once daily for days 3 to 28)
Trial: 25624327
Drug: High-dose isavuconazole
RxNorm normalized name: isavuconazole
DrugBank: Isavuconazole (DB11633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose isavuconazole (doses doubled from low-dose regimen)
Trial: 25624403
Drug: Arachidonic acid
RxNorm normalized name: Arachidonic acid
DrugBank: Arachidonic Acid (DB04557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arachidonic acid (ARA) 10 mg/kg per day for 15 days
Trial: 25624403
Drug: Praziquantel (PZQ)
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel (PZQ) 40 mg/kg single dose
Trial: 25624403
Drug: Biochemical and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biochemical and immunological profiles after ARA therapy
Trial: 25627002
Drug: IMO-2055 (0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-2055 (0.16 mg/kg)
Trial: 25627002
Drug: IMO-2055 (0.32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-2055 (0.32 mg/kg)
Trial: 25627002
Drug: IMO-2055 (0.48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-2055 (0.48 mg/kg)
Trial: 25629663
Drug: ChAd3 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd3 vaccine (1×10(10) viral particles)
Trial: 25629663
Drug: ChAd3 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd3 vaccine (2.5×10(10) viral particles)
Trial: 25629663
Drug: ChAd3 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd3 vaccine (5×10(10) viral particles)
Trial: 25629663
Drug: ChAd3 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd3 vaccine followed by MVA booster
Trial: 25629663
Drug: ChAd3 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd3 vaccine
Trial: 25631362
Drug: Home-based mindfulness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based mindfulness therapy
Trial: 25632070
Drug: SB939 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB939 (60 mg/day every other day for 3 of 4 weeks)
Trial: 25633714
Drug: Pradigastat 20
RxNorm normalized name: Pradigastat
DrugBank: Pradigastat (DB12866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradigastat 20 mg single oral dose in patients with mild hepatic impairment
Trial: 25633714
Drug: Pradigastat 20
RxNorm normalized name: Pradigastat
DrugBank: Pradigastat (DB12866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradigastat 20 mg single oral dose in patients with moderate hepatic impairment
Trial: 25633714
Drug: Pradigastat 20
RxNorm normalized name: Pradigastat
DrugBank: Pradigastat (DB12866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradigastat 20 mg single oral dose in patients with severe hepatic impairment
Trial: 25633882
Drug: Ranibizumab 0.5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5-mg
Trial: 25633882
Drug: Ranibizumab 2.0-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 2.0-mg
Trial: 25634486
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cystoscopy and nCLE
Trial: 25635138
Drug: Dasatinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (100 mg daily)
Trial: 25637055
Drug: PAT-SM6 (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAT-SM6 (0.3, 1, 3, and 6 mg/kg)
Trial: 25637379
Drug: Fluorouracil, epirubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil, epirubicin, and cyclophosphamide (FEC) regimen with granulocyte colony-stimulating factor support followed by weekly paclitaxel
Trial: 25637379
Drug: Dose-density regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-density regimen with FEC followed by weekly paclitaxel
Trial: 25639506
Drug: Cabazitaxel 25
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 25 mg/m² every 3 weeks with prednisolone 10 mg daily for up to 10 cycles
Trial: 25642145
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg dose
Trial: 25642392
Drug: Weekly multimodal
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly multimodal MRI follow-up including diffusion tensor imaging (DTI), perfusion imaging, FLAIR, and contrast-enhanced 3D T1-weighted MR.
Trial: 25642774
Drug: Evaluation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of insulin secretory kinetics
Trial: 25644339
Drug: Bolus EAA
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus EAA feeding (15 g mixed-EAA as a single dose)
Trial: 25644339
Drug: Spread EAA
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spread EAA feeding (15 g mixed-EAA in 4 fractions at 45-min intervals)
Trial: 25644958
Drug: Chimerism-based immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimerism-based immunotherapy (IT) with fast withdrawal of immunosuppression (FWI) and donor lymphocyte infusions (DLI)
Trial: 25644958
Drug: Chimerism-based immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimerism-based immunotherapy (IT)
Trial: 25645025
Drug: Influenza A/California/2009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza A/California/2009 (H1N1) virus, intranasally inoculated at increasing doses (up to 3.5 × 10(6) TCID50)
Trial: 25645025
Drug: Influenza A/California/2009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza A/California/2009 (H1N1) virus, highest dose (3.5 × 10(6) TCID50)
Trial: 25645660
Drug: IV voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV voriconazole (8.1±2.1 mg/kg/day)
Trial: 25645660
Drug: SBECD (129±33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBECD (129±33 mg/kg/day)
Trial: 25645668
Drug: Uncertain treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncertain treatment preferences
Trial: 25645668
Drug: Doctor communication
RxNorm normalized name: Doctor's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doctor communication about treatment options
Trial: 25645668
Drug: Life-sustaining treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life-sustaining treatments for more than 7 days
Trial: 25648230
Drug: Laparoscopic surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic surgery with intra-abdominal pressure of 9 mmHg (Group L)
Trial: 25648341
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CyA) treatment
Trial: 25648341
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CyA) treatment for approximately 6 months
Trial: 25649171
Drug: Subvirion H3N2v
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subvirion H3N2v vaccine (15 µg of hemagglutinin/dose), administered in 2 doses 21 days apart.
Trial: 25651449
Drug: Rate-control drugs
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rate-control drugs
Trial: 25651449
Drug: Overall anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall anticoagulant therapy
Trial: 25651830
Drug: Bortezomib (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.3 mg/m²) + Dexamethasone (20 mg for 2 days with each Bz dose)
Trial: 25652454
Drug: PF-05212384, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-05212384, administered intravenously once weekly at a maximum-tolerated dose (MTD) of 154 mg
Trial: 25653396
Drug: Abbott RealTime
RxNorm normalized name: LANCET,ABBOTT THIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbott RealTime HCV RNA assay (<12 IU/ml)
Trial: 25653396
Drug: High Pure
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Pure System or Abbott RealTime (<12 IU/ml)
Trial: 25653826
Drug: Quetiapine immediate-release
RxNorm normalized name: quetiapine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine immediate-release (IR)